Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2211-2220 Newer>

The Motley Fool July 22, 2005 Stephen D. Simpson	Big Miss Afflicts Affymetrix Gee-whiz technology doesn't always mean gee-whiz growth. While the facilitator of genetics research and drug development enjoyed has recovered significantly from its lows, long-term investors saw another market thrashing on a disappointing outlook.
The Motley Fool July 22, 2005 Karl Thiel	Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine.
The Motley Fool July 21, 2005 Stephen D. Simpson	Merck Is No Quack Weighing the pros and cons, it appears that Merck's stock is trading pretty much where it should be. What does make the story a bit more interesting is that robust dividend, which is currently yielding almost 4.8%.
The Motley Fool July 21, 2005 Stephen D. Simpson	Apria's Last Gasps? The home health-care provider looks to rebuild its growth, but may instead decide to sell out. Even if the company doesn't sell, though, investors could still be rewarded as long as they're willing to hang on and wait.
The Motley Fool July 21, 2005 Stephen D. Simpson	Schering Plows Ahead Strong sales are driving this turnaround. As long as the pharma continues to make progress with its legal and regulatory issues and simultaneously continue to deliver solid financial results, the valuation and stock price will likely work themselves out favorably over time.
The Motley Fool July 21, 2005 Tom Taulli	Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.
The Motley Fool July 21, 2005 Stephen D. Simpson	Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well.
The Motley Fool July 20, 2005 Karl Thiel	Pride and Preclinicals Biotech ArQule has surged, but take its early-stage data with a grain of salt.
The Motley Fool July 20, 2005 Warren Gump	Will Perrigo's Prescription Work? Perrigo, the nation's largest maker of private-label over-the-counter (OTC) drugs, is setting new 52-week lows. Nonetheless, if management delivers as it has over the past few years, the longer-term outlook looks promising.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
<Older 2211-2220 Newer> Return to current articles.